Review
Round cell sarcomas beyond Ewing: emerging entities
Cristina Antonescu,
Corresponding Author
Cristina Antonescu
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Address for correspondence: C Antonescu, Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. e-mail: [email protected]Search for more papers by this authorCristina Antonescu,
Corresponding Author
Cristina Antonescu
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Address for correspondence: C Antonescu, Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. e-mail: [email protected]Search for more papers by this authorAbstract
Primitive small blue round cell tumours (SBRCT) of childhood and young adults have been problematic to diagnose and classify. Diagnosis is also complicated in cases with atypical morphology, aberrant immunoprofiles and unusual clinical presentations. Even with the increased use of ancillary techniques in archival material, such as immunohistochemistry and molecular/genetic methods, a proportion of these tumours cannot be subclassified into specific histological types. A subset of tumours resembling microscopically the Ewing sarcoma family of tumours (EFT), being composed of primitive small round cells and occurring in paediatric or young adult age groups, remain unclassified, being negative for EWSR1, SS18(SYT), DDIT3(CHOP) and FOXO1(FKHR) gene rearrangements by FISH/RT–PCR. A small number of cases sharing the undifferentiated EFT appearance have been characterized recently carrying BCOR–CCNB3 or CIC–DUX4 fusions. However, based on the somewhat limited number of cases, it remains unclear if these newly defined genetic entities belong to any of the pre-existing clinicopathological disorders or represent altogether novel conditions. This review presents the latest molecular findings related to these SBRCTs, beyond the common EWSR1–ETS fusions. Specific attention has been paid to morphological features not associated typically with classic EFT, and the value of ancillary tests that can be applied when dealing with EWSR1-negative SBRCTs is discussed.
References
- 1Ahmad R, Mayol BR, Davis M et al. Extraskeletal Ewing's sarcoma. Cancer 1999; 85; 725–731.
10.1002/(SICI)1097-0142(19990201)85:3<725::AID-CNCR23>3.0.CO;2-2 CAS PubMed Web of Science® Google Scholar
- 2Fellinger EJ, Garin-Chesa P, Triche TJ et al. Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2. Am. J. Pathol. 1991; 139; 317–325.
- 3Riopel M, Dickman PS, Link MP et al. MIC2 analysis in pediatric lymphomas and leukemias. Hum. Pathol. 1994; 25; 396–399.
- 4Gu M, Antonescu CR, Guiter G et al. Cytokeratin immunoreactivity in Ewing's sarcoma: prevalence in 50 cases confirmed by molecular diagnostic studies. Am. J. Surg. Pathol. 2000; 24; 410–416.
- 5Delattre O, Zucman J, Plougastel B et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359; 162–165.
- 6Delattre O, Zucman J, Melot T et al. The Ewing family of tumors – a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N. Engl. J. Med. 1994; 331; 294–299.
- 7May WA, Gishizky ML, Lessnick SL et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc. Natl Acad. Sci. USA 1993; 90; 5752–5756.
- 8Ginsberg JP, de Alava E, Ladanyi M et al. EWS–FLI1 and EWS–ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J. Clin. Oncol. 1999; 17; 1809–1814.
- 9Wang WL, Patel NR, Caragea M et al. Expression of ERG, an ETS family transcription factor, identifies ERG-rearranged Ewing sarcoma. Mod. Pathol. 2012; 25; 1378–1383.
- 10Miettinen M, Wang ZF, Paetau A et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am. J. Surg. Pathol. 2011; 35; 432–441.
- 11Jeon IS, Davis JN, Braun BS et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 1995; 10; 1229–1234.
- 12Kaneko Y, Yoshida K, Handa M et al. Fusion of an ETS-family gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Genes Chromosom. Cancer 1996; 15; 115–121.
10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6 CAS PubMed Web of Science® Google Scholar
- 13Peter M, Couturier J, Pacquement H et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 1997; 14; 1159–1164.
- 14Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 2001; 20; 5747–5754.
- 15Zucman J, Melot T, Desmaze C et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J. 1993; 12; 4481–4487.
- 16Plougastel B, Zucman J, Peter M et al. Genomic structure of the EWS gene and its relationship to EWSR1, a site of tumor-associated chromosome translocation. Genomics 1993; 18; 609–615.
- 17Zoubek A, Dockhorn-Dworniczak B, Delattre O et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J. Clin. Oncol. 1996; 14; 1245–1251.
- 18Romeo S. Dei Tos AP. Soft tissue tumors associated with EWSR1 translocation. Virchows Arch. 2010; 456; 219–234.
- 19Aryee DN, Sommergruber W, Muehlbacher K et al. Variability in gene expression patterns of Ewing tumor cell lines differing in EWS–FLI1 fusion type. Lab. Invest. 2000; 80; 1833–1844.
- 20de Alava E, Kawai A, Healey JH et al. EWS–FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J. Clin. Oncol. 1998; 16; 1248–1255.
- 21Le Deley MC, Delattre O, Schaefer KL et al. Impact of EWS–ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J. Clin. Oncol. 2010; 28; 1982–1988.
- 22Bridge JA, Fidler ME, Neff JR et al. Adamantinoma-like Ewing's sarcoma: genomic confirmation, phenotypic drift. Am. J. Surg. Pathol. 1999; 23; 159–165.
- 23Folpe AL, Goldblum JR, Rubin BP et al. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am. J. Surg. Pathol. 2005; 29; 1025–1033.
- 24Weinreb I, Goldstein D, Perez-Ordonez B. Primary extraskeletal Ewing family tumor with complex epithelial differentiation: a unique case arising in the lateral neck presenting with Horner syndrome. Am. J. Surg. Pathol. 2008; 32; 1742–1748.
- 25Kikuchi Y, Kishimoto T, Ota S et al. Adamantinoma-like Ewing family tumor of soft tissue associated with the vagus nerve: a case report and review of the literature. Am. J. Surg. Pathol. 2013; 37; 772–779.
- 26Mastrangelo T, Modena P, Tornielli S et al. A novel zinc finger gene is fused to EWS in small round cell tumor. Oncogene 2000; 19; 3799–3804.
- 27Wang L, Bhargava R, Zheng T et al. Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS–SP3 fusion and of additional cases with the EWS–ETV1 and EWS–FEV fusions. J. Mol. Diagn. 2007; 9; 498–509.
- 28Szuhai K, Ijszenga M, de Jong D et al. The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin. Cancer Res. 2009; 15; 2259–2268.
- 29Sumegi J, Nishio J, Nelson M et al. A novel t(4;22)(q31;q12) produces an EWSR1–SMARCA5 fusion in extraskeletal Ewing sarcoma/primitive neuroectodermal tumor. Mod. Pathol. 2011; 24; 333–342.
- 30Shing DC, McMullan DJ, Roberts P et al. FUS/ERG gene fusions in Ewing's tumors. Cancer Res. 2003; 63; 4568–4576.
- 31Berg T, Kalsaas AH, Buechner J et al. Ewing sarcoma–peripheral neuroectodermal tumor of the kidney with a FUS-ERG fusion transcript. Cancer Genet. Cytogenet. 2009; 194; 53–57.
- 32Ng TL, O'Sullivan MJ, Pallen CJ et al. Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. J. Mol. Diagn. 2007; 9; 459–463.
- 33Italiano A, Sung YS, Zhang L et al. High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes Chromosom. Cancer 2012; 51; 207–218.
- 34Richkind KE, Romansky SG, Finklestein JZ. t(4;19)(q35;q13.1): a recurrent change in primitive mesenchymal tumors? Cancer Genet. Cytogenet. 1996; 87; 71–74.
- 35Yoshimoto M, Graham C, Chilton-MacNeill S et al. Detailed cytogenetic and array analysis of pediatric primitive sarcomas reveals a recurrent CIC–DUX4 fusion gene event. Cancer Genet. Cytogenet. 2009; 195; 1–11.
- 36Kawamura-Saito M, Yamazaki Y, Kaneko K et al. Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum. Mol. Genet. 2006; 15; 2125–2137.
- 37Alaggio R, Bisogno G, Rosato A et al. Undifferentiated sarcoma: does it exist? A clinicopathologic study of 7 pediatric cases and review of literature. Hum. Pathol. 2009; 40; 1600–1610.
- 38Sirvent N, Trassard M, Ebran N et al. Fusion of EWSR1 with the DUX4 facioscapulohumeral muscular dystrophy region resulting from t(4;22)(q35;q12) in a case of embryonal rhabdomyosarcoma. Cancer Genet. Cytogenet. 2009; 195; 12–18.
- 39Rakheja D, Goldman S, Wilson KS et al. Translocation (4;19)(q35;q13.1)-associated primitive round cell sarcoma: report of a case and review of the literature. Pediatr. Dev. Pathol. 2008; 11; 239–244.
- 40Graham C, Chilton-MacNeill S, Zielenska M et al. The CIC–DUX4 fusion transcript is present in a subgroup of pediatric primitive round cell sarcomas. Hum. Pathol. 2012; 43; 180–189.
- 41Lemmers RJ, van der Vliet PJ, Klooster R et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 2010; 329; 1650–1653.
- 42Roch F, Jimenez G, Casanova J. EGFR signalling inhibits Capicua-dependent repression during specification of Drosophila wing veins. Development 2002; 129; 993–1002.
- 43Lee CJ, Chan WI, Cheung M et al. CIC, a member of a novel subfamily of the HMG-box superfamily, is transiently expressed in developing granule neurons. Brain Res. Mol. Brain Res. 2002; 106; 151–156.
- 44Lee CJ, Chan WI, Scotting PJ. CIC, a gene involved in cerebellar development and ErbB signaling, is significantly expressed in medulloblastomas. J. Neurooncol. 2005; 73; 101–108.
- 45Lemmers RJ, van der Vliet PJ, van der Gaag KJ et al. Worldwide population analysis of the 4q and 10q subtelomeres identifies only four discrete interchromosomal sequence transfers in human evolution. Am. J. Hum. Genet. 2010; 86; 364–377.
- 46van Geel M, Dickson MC, Beck AF et al. Genomic analysis of human chromosome 10q and 4q telomeres suggests a common origin. Genomics 2002; 79; 210–217.
- 47Snider L, Geng LN, Lemmers RJ et al. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet. 2010; 6; e1001181.
- 48Roberts P, Browne CF, Lewis IJ et al. 12q13 abnormality in rhabdomyosarcoma. A nonrandom occurrence? Cancer Genet. Cytogenet. 1992; 60; 135–140.
- 49Pierron G, Tirode F, Lucchesi C et al. A new subtype of bone sarcoma defined by BCOR–CCNB3 gene fusion. Nat. Genet. 2012; 44; 461–466.
- 50Toomey EC, Schiffman JD, Lessnick SL. Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene 2010; 29; 4504–4516.
- 51Fan Z, Yamaza T, Lee JS et al. BCOR regulates mesenchymal stem cell function by epigenetic mechanisms. Nat. Cell Biol. 2009; 11; 1002–1009.
- 52Nguyen TB, Manova K, Capodieci P et al. Characterization and expression of mammalian cyclin b3, a prepachytene meiotic cyclin. J. Biol. Chem. 2002; 277; 41960–41969.
- 53Pawel BR, Hamoudi AB, Asmar L et al. Undifferentiated sarcomas of children: pathology and clinical behavior – an Intergroup Rhabdomyosarcoma study. Med. Pediatr. Oncol. 1997; 29; 170–180.
10.1002/(SICI)1096-911X(199709)29:3<170::AID-MPO3>3.0.CO;2-A CAS PubMed Web of Science® Google Scholar
- 54Sebire NJ, Ramsay AD, Levitt G et al. Aberrant immunohistochemical expression in nonrhabdomyosarcoma soft tissue sarcomas of infancy: retrospective review of clinical material. Pediatr. Dev. Pathol. 2002; 5; 579–586.
- 55Mosquera JM, Sboner A, Zhang L et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosom. Cancer 2013; 52; 538–550.
Citing Literature
